In a landmark decision, the World Health Assembly has adopted its first-ever resolution specifically addressing steatotic liver disease (SLD), acknowledging it as a critical gap in existing noncommunicable disease strategies. This watershed moment elevates fatty liver disease from obscurity to the highest level of international health governance, affecting an estimated 1.5 billion people worldwide.
The resolution represents a significant paradigm shift in global health policy. For decades, SLD has been systematically overlooked despite affecting roughly one in five adults globally, making it one of the most prevalent liver conditions worldwide. The WHO’s formal recognition underscores the urgent need to integrate SLD prevention, diagnosis, and management into existing NCD frameworks and healthcare systems.
This decision signals a renewed commitment to comprehensive noncommunicable disease strategies that extend beyond the traditionally focused “big four” conditions. Member states are now called to strengthen healthcare systems for better detection and management of SLD, marking a pivotal step forward in addressing this long-neglected public health challenge.
Read the full article on GMJ Newsroom.
Was this article helpful?
